Glutamine Supplementation

Status Withdrawn

Clinical Trial Summary

Earlier studies showed a benefit in survival when glutamine was given intravenously and these studies lead to recommendations that glutamine should be given to critically ill patients. The ESPEN guidelines recommend 0,2-0,4 g/kg/d intravenous glutamine added to standard parenteral nutrition .

Until recently it was not possible to obtain a plasma glutamine level fast enough to consider the result for clinical decision making. With the availability of a Point of Care (POCT) measurement of plasma glutamine level a measurement can be performed short after the collection of blood. This offers the possibility to identify a patient with a low plasma glutamine level shortly after admission and use repeated measurements for evaluation of the response to supplementation of glutamine.

Clinical Trial Description

- At admission (day 0) a plasma glutamine level is measured. The measurement can be performed from blood taken for the first arterial blood gas analysis. Patients are eligible for the study when the plasma glutamine level is lower than 420 µmol/l.

- After informed consent is obtained patients are randomised to receive enteral glutamine or not ( the control group). Enteral glutamine supplementation is started (day 1) at a dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams of L-glutamine ( Glutaperos®, GLNP Life Sciences).

- Enteral glutamine supplementation will be given for a maximum of 10 days or until the patient is discharged from the ICU.

- Plasma glutamine levels will be measured four times a day, at 06.00, 12.00, 18.00 and 00.00 hours, concurrently with the standard arterial blood gas analyses so no extra blood is taken from the patient.

- On day 3 at 12.00 hours the dose of glutamine will be increased to 3 times 2 sachets if plasma glutamine level is still below 420 µmol/l.

- From day 3 ( 12.00 hrs) until day 10 ( end of study) the dosage of enteral glutamine will be evaluated daily at 12.00 hours. When the plasma glutamine level is higher than 420 µmol/l the dosage of enteral glutamine will be adjusted according to the schedule below.

- In patients who randomized to the control group, the plasma glutamine level will be measured daily at 12.00 hr concurrently with standard arterial blood gas analysis ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02738762
Study type	Interventional
Source	Medical Centre Leeuwarden
Contact
Status	Withdrawn
Phase	N/A
Start date	November 15, 2017
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05921656` - Construction and Evaluation of Airway Leakage Risk Model of Patients With Endotracheal Tube
Recruiting	`NCT03941002` - Continuous Evaluation of Diaphragm Function	N/A
Withdrawn	`NCT04288076` - The Brain and Lung Interaction (BALI) Study	N/A
Completed	`NCT03031860` - Semi-quantitative Cough Strength Score (SCSS)	N/A
Completed	`NCT02545621` - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Completed	`NCT02312869` - Local Assessment of Management of Burn Patients	N/A
Completed	`NCT01885442` - TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients	N/A
Completed	`NCT01204281` - Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients	Phase 4
Terminated	`NCT01059929` - Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)	Phase 4
Completed	`NCT00824239` - Intermittent Sedation Versus Daily Interruption of Sedation in Mechanically Ventilated Patients	Phase 3
Completed	`NCT00529347` - Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects of Changes in Ventilator Parameters on Breathing Pattern	Phase 1
Unknown status	`NCT00260676` - Protective Ventilatory Strategy in Potential Organ Donors	Phase 3
Terminated	`NCT00205517` - Sedation and Psychopharmacology in Critical Care	N/A
Completed	`NCT03281785` - Ultrasound of Diaphragmatic Musculature in Mechanically Ventilated Patients.	N/A
Recruiting	`NCT04110613` - RCT: Early Feeding After PEG Placement	N/A
Completed	`NCT04410783` - The Emergency Department Sedation Pilot Trial	N/A
Recruiting	`NCT04821453` - NAVA vs. CMV Crossover in Severe BPD	N/A
Completed	`NCT03930147` - Ventilation With ASV Mode in Children	N/A
Recruiting	`NCT05029167` - REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study)	N/A
Recruiting	`NCT04849039` - Lung Microbiota and VAP Development (PULMIVAP)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.